Want to see HK:1244 full AI Analyst Report?
1244 Stock Chart & Stats
HK$6.14
-HK$0.10(-2.80%)
At close: 4:00 PM EST
HK$6.14
-HK$0.10(-2.80%)
Day’s Range― - ―
52-Week RangeHK$1.82 - HK$8.38
Previous CloseN/A
Volume120.00K
Average Volume (3M)300.15K
Market Cap
HK$684.17M
Enterprise ValueHK$301.14
Total Cash (Recent Filing)HK$394.59M
Total Debt (Recent Filing)HK$171.36M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding258,177,000
10 Day Avg. Volume39,150
30 Day Avg. Volume300,150
Financial Highlights & Ratios
PEG Ratio1.66
Price to Book (P/B)1.97
Price to Sales (P/S)3.30
P/FCF Ratio-7.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginA gross margin near 92% indicates that approved products and commercial activities can generate substantial value after direct costs. If maintained, this provides a strong foundation for funding research, development, commercialization, and eventual operating leverage as revenue stabilizes.
Losses Are NarrowingThe substantial reduction in losses versus 2022–2023 suggests improving cost discipline, product mix, or operating efficiency. Although profitability has not been achieved, continued progress could reduce the scale of future funding needs and improve the company’s path toward sustainable earnings.
Manageable LeverageA debt-to-equity ratio near 0.26 suggests the company is not currently heavily debt-funded, preserving some financial flexibility for oncology development and commercialization. Lower leverage also limits interest-related pressure compared with a more debt-dependent balance sheet, despite ongoing losses.
Bears Say
Revenue ContractionA revenue decline of roughly 23% weakens operating leverage and makes it harder to absorb the fixed costs of research, development, manufacturing, and commercialization. Continued contraction could delay scale benefits and increase the pressure on the company to secure new product or market growth.
Persistent Operating And Net LossesLarge operating and net losses show that the company’s strong gross margin has not yet translated into sustainable profitability. Persistent losses can continue eroding equity, constrain investment capacity, and leave the business dependent on future improvement in revenue, costs, or product economics.
Ongoing Cash BurnNegative operating and free cash flow mean the business continues consuming cash to fund operations rather than internally financing its development and commercialization activities. If this burn persists, reliance on financing may increase and could limit strategic flexibility during periods of weaker revenue.
3D Medicines, Inc. News
1244 FAQ
What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$1.82 and its highest was HK$8.38 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$684.17M.
When is 3D Medicines, Inc.’s upcoming earnings report date?
3D Medicines, Inc.’s upcoming earnings report date is Apr 01, 2027 which is in 189 days.
How were 3D Medicines, Inc.’s earnings last quarter?
3D Medicines, Inc. released its earnings results on Aug 31, 2026. The company reported -HK$0.395 earnings per share for the quarter.
Is 3D Medicines, Inc. overvalued?
According to Wall Street analysts 3D Medicines, Inc.’s price is currently Overvalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
3D Medicines, Inc. reported an EPS of -HK$0.395 in its last earnings report. Following the earnings report the stock price went down -4.432%.
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
3D Medicines, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
3D Medicines, Inc.
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Technical Analysis
Alphamab Oncology
―
JW (Cayman) Therapeutics Co. Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―